HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos (t) ide analogues
Background & Aims In treated patients with chronic hepatitis B (CHB) who have achieved
complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface
antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of
hepatocellular carcinoma (HCC) and hepatic events in nucleos (t) ide analogue (NA)-treated
patients with and without HBsAg seroclearance. Methods We performed a territory-wide
retrospective cohort study on all patients with CHB who had received entecavir and/or …
complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface
antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of
hepatocellular carcinoma (HCC) and hepatic events in nucleos (t) ide analogue (NA)-treated
patients with and without HBsAg seroclearance. Methods We performed a territory-wide
retrospective cohort study on all patients with CHB who had received entecavir and/or …
